EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic Targeting of the Cancer Microbiome and Metabolome: Ongoing Trials and Future Directions for the Surgical Oncologist

Erika J Nachman iD, Taylor Neilson iD, Michael G White iD

Journal of Surgical Oncology · 09.11.2026

DOI: 10.1002/jso.70451 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Surgical Oncology, online erschienen am 09.11.2026. Verfasst von Erika J Nachman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colon & Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA. Die Arbeit nennt 64 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of the human microbiome in cancer development, progression, and response to therapy has moved from correlative curiosity to demonstrated impact on tumor biology. This represents a critical factor for surgical oncologists as they not only resect these tumors, but also direct perioperative antimicrobial exposure and increasingly co‐manage neoadjuvant and surveillance pathways in which microbial state may predict and modify response. This review summarizes the basis for therapeutic modulation of the cancer microbiome and metabolome in a contemporary clinical‐trial landscape across four broad strategies: additive (fecal microbiota transplantation, defined consortia, and live biotherapeutic products), subtractive (targeted antimicrobials), dietary and metabolome‐directed interventions, and engineered or next‐generation platforms. Particular attention is given to subtractive approaches in colon and rectal cancer and to the underexplored perioperative interface between the microbiome and surgical outcomes such as anastomotic leak. We outline the principal methodological and translational obstacles, including low‐biomass contamination, causal inference, unintended antibiotic effects, and product standardization. Looking ahead, we propose roles for surgeons across the care continuum, from biospecimen stewardship and trial referral to integration of microbiome and circulating tumor DNA signals in surveillance.

Schlagwörter

Stichwörter der Autor:innen

clinical trialsfecal microbiota transplantationintratumoral bacteriametabolomemicrobiomerectal cancersurgical oncology

Autor:innen und Institutionen

  • Department of Colon & Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Platform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, USA.

ORCID-Profile: Erika J Nachman, Taylor Neilson, Michael G White

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Nachman, E. J., Neilson, T., & White, M. G. (2026). Therapeutic Targeting of the Cancer Microbiome and Metabolome: Ongoing Trials and Future Directions for the Surgical Oncologist. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70451

Vancouver

Nachman EJ, Neilson T, White MG. Therapeutic Targeting of the Cancer Microbiome and Metabolome: Ongoing Trials and Future Directions for the Surgical Oncologist. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70451

BibTeX
@article{Nachman2026,
  author = {Nachman, Erika J and Neilson, Taylor and White, Michael G},
  title = {Therapeutic Targeting of the Cancer Microbiome and Metabolome: Ongoing Trials and Future Directions for the Surgical Oncologist},
  journal = {Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1002/jso.70451}
}
Kostenlos starten →